Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.42 |
| ▸ | HTR3B | O95264 | 5/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067060 | 0.82 | CHKA (0.34) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL918905 | 0.82 | CHKA (0.39) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL185803 | 0.81 | HPGD (0.39) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL22530015 | 0.79 | HSD17B10 (0.34) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL18228552 | 0.78 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL526372 | 0.78 | PLD1 (0.44) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL14931430 | 0.77 | PDE10A (0.36) | ALDH1A1 | |
| SCHEMBL12468806 | 0.75 | OGA (0.38) | — | |
| SCHEMBL994898 | 0.75 | L3MBTL3 (0.37) | HTR3AHRH4HRH3KDM4EALDH1A1 | |
| SCHEMBL22530356 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072890-B1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3072890-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI Pharma, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9296732-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | UNIV LELAND STANFORD JUNIOR (US) | 2015-11-19 | — | — | US | disclosed |
| US-9085570-B2 | Substituted benzamides and their uses | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150072976-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | ARAVIVE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| EP-2838534-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | The Board of Trustees of The Leland Stanford Junior University (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-23 | — | — | US | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| WO-2013155338-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-10-17 | — | — | WO | disclosed |
| EP-2451802-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2012051117-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005119-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | WO | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | HTR3A 2905/4885HTR3E 3015/4885HTR3B 3190/4885 |
| US-20150329503-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | NISCH, BTD, NAAA | HTR3A 3043/4885HTR3E 2802/4885HTR3B 2673/4885 |
| US-20140024649-A1 | Substituted Benzamides and Their Uses | NISCH, BTD, NAAA | HTR3A 3043/4885HTR3E 2802/4885HTR3B 2673/4885 |
| US-20150072976-A1 | SUBSTITUTED BENZAMIDES AND THEIR USES | NISCH, BTD, NAAA | HTR3A 3043/4885HTR3E 2802/4885HTR3B 2673/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HTR3A 2646/4885HTR3E 2911/4885HTR3B 3144/4885 |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | TYMP, TYMS, CCNI | HTR3A 2199/4885HTR3E 2314/4885HTR3B 2333/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HTR3A 2646/4885HTR3E 2911/4885HTR3B 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.